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Every century is characterized by scientific achievements 
that become its historical landmarks and symbols. The 
previous century will be remembered for its significant 
discoveries relating to theoretical physics, chemistry, and 
biology, including stem cells. This latter discovery will 
be especially memorable for having opened the door to 
the development of regenerative medicine. There is no 
doubt that stem cell-based therapies will be regarded 
by future generations as a landmark achievement of the 
twenty-first century. While this is a huge challenge for 
medical science, there is hope that new therapies will 
be developed that enable several so-far-incurable dis-
eases to be cured, prolonging life span and improving 
the quality of life. Clinical and Translational Medicine 
will keep pace with these new challenges by opening a 
new section dedicated to stem cell therapies, which will 
offer original peer-reviewed articles, reviews, editorials, 
commentaries, and perspectives. We will also welcome 
papers focused on bioethics, clinical regulations, clini-
cal guidelines, and methodologies, and brief reports on 
experimental and clinical applications of stem cells. We 
were very lucky to recruit outstanding editorial board 
members for this section.
There are many journals dedicated to regenerative 
medicine. Nevertheless, we would like to be unique in 
this field in some way. Since the paradigms of science 
shift, and, as Albert Einstein once stated, “blind belief in 
authority is the greatest enemy of truth”, we would like to 
launch a new section that will provide a forum for new 
and challenging ideas and report progress in regenera-
tive medicine. There are still many questions that need 
to be answered with hypothesis testing by independent 
groups. We are aware that our current work will require 
new generations of scientists not only to verify many of 
the current paradigms but also to carry forward progress 
in regenerative medicine in the coming decades.
Regenerative medicine has two main goals. The first 
is to employ stem cells efficiently and safely in therapies 
for injured organs and tissues. It is believed that, in the 
future, the transplantation of entire organs will be largely 
replaced by the transplantation of a suspension of stem 
cells directed to the given organ, alone or in combination 
with organic or synthetic scaffolds, which will perform 
the task of rebuilding the injured tissues. The second 
important and parallel goal of regenerative medicine is 
to develop strategies that will improve quality of life and 
longevity by improving the regenerative potential and 
proper functioning of adult stem cells residing in various 
organs.
Some of the most important challenges and topics that 
will be covered by this new section of Clinical and Trans-
lational Medicine are listed below.
Search for the most efficient stem cell for clinical appli-
cation The search for stem cells that can be safely and 
efficiently employed for regeneration of damaged solid 
organs continues. Ideal for this purpose would be pluri-
potent stem cells, which, according to their definition, 
have broad potential to differentiate into cells belonging 
to the three germ layers [1]. For almost 20  years, there 
have been unsuccessful attempts to harness embryonic 
stem cells isolated from embryos, which has been con-
troversial from an ethical point of view. A more promis-
ing source is induced pluripotent stem cells, which are 
generated by genetic modification of adult somatic cells. 
Unfortunately, both embryonic stem cells and induced 
pluripotent stem cells bear a similar risk of tumor for-
mation after injection into the host [1, 2]. On the other 
hand, stem cells isolated from postnatal tissues, such as 
bone marrow, mobilized peripheral blood, umbilical cord 
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blood, umbilical cord, placenta, fat, or epidermis, are 
the only stem cells that have been employed safely in the 
clinic so far. Since these are already committed to certain 
lineages, the question remains whether adult tissues also 
harbor other stem cells with much broader differentia-
tion potential across germ layers that are multi- or pluri-
potent. These investigations and the search for such cells 
have prompted to challenge the accepted hierarchy of the 
stem cell compartment in adult tissues [1, 2].
Paracrine- and extracellular microvesicle-mediated 
effects of stem cell therapies While mesenchymal stem 
cells, cardiac stem cells, and hematopoietic stem cells are 
employed in the clinic, there has been a lack of convinc-
ing documentation for donor–recipient chimerism in 
the solid organs treated, and most studies indicate that a 
mechanism other than transdifferentiation of cells plays a 
role, most likely involving the paracrine effects of growth 
factors, cytokines, chemokines, bioactive lipids, and 
extracellular microvesicles released from cells employed 
as cellular therapeutics [3, 4]. These beneficial parac-
rine mechanisms could be harnessed more efficiently to 
regenerate damaged organs. Stem cells could be modified 
to secrete more of the paracrine factors that inhibit apop-
tosis in damaged tissues and enhance vascularization. 
One of the immediate and safe applications for induced 
pluripotent stem cells would be their application as cell 
lines for producing therapeutic extracellular microvesi-
cles [3, 4].
Molecular mechanisms involved in stem cell pluripo-
tency, quiescence, proliferation, and differentiation The 
number of stem cells isolated from adult tissues is usually 
very limited. In particular, the most primitive stem cells 
(from a developmental point of view) are present at very 
low frequencies in adult tissues. To overcome this prob-
lem, different ex vivo expansion strategies have been pro-
posed to amplify the numbers of these cells so that they 
can be employed more efficiently in the clinic. Unfortu-
nately, optimized expansion protocols for the most prim-
itive stem cells have not been described so far, and during 
expansion these most primitive cells decrease in number 
due to their differentiation into more mature progenitors 
[5]. An efficient expansion strategy requires identifica-
tion of the set of genes that balances pluripotency, multi-
potency, and stem cell self-renewal with differentiation. 
Unravelling the mechanisms that govern the quiescence 
of the most primitive stem cells in adult tissues is of pri-
mary importance in developing expansion strategies for 
these rare cells that will allow their application in the 
clinic [6]. An important additional goal of regenerative 
medicine is to develop strategies that enhance quality of 
life and longevity by improving the regenerative poten-
tial and proper functioning of adult stem cells residing in 
various organs. This could be achieved by application of 
anti-aging drugs, caloric restriction, or regular physical 
activity [7]. Thus, anti-aging strategies for stem cells will 
be one of the important topics of this new section.
Mechanisms that govern stem cell trafficking, including 
mobilization and homing to damaged tissues It is known 
that stem cells are endowed with migratory potential 
and that they are released from their niches in a pro-
cess known as mobilization. In the reverse process, stem 
cells settle into niches during so-called homing. Mecha-
nisms that govern mobilization and homing have been 
best studied so far in hematopoietic stem cells [1, 8–10]. 
However, evidence has accumulated that other types of 
stem cells, such as mesenchymal stem cells, also undergo 
mobilization into peripheral blood. Therefore, in order 
to enrich peripheral blood in circulating stem cells, more 
efficient mobilization protocols have to be developed. On 
the other hand, we need to identify the mechanisms and 
all the regulatory factors (e.g., chemokines, growth fac-
tors, bioactive lipids, extracellular nucleotides) that gov-
ern trafficking of stem cells in the body. It is also crucial 
to develop optimal strategies for harvesting stem cells 
and to establish protocols for their delivery to damaged 
tissues. Another important issue is delivery of stem cells 
using special scaffolds that accelerate organ regeneration.
Clinical ethics, regulations, trials, protocols, and prac-
tices for stem cell therapies All new experimental treat-
ment strategies in regenerative medicine must ultimately 
be tested in the clinic. This approach requires dealing 
with ethical and regulatory issues and has to be based on 
solid clinical development and approval by appropriate 
board protocols. It is obvious that clinical application of 
stem cells that follows good medical practice guidelines 
will require unified procedures and protocols so that tri-
als can be compared between different centers [5, 11, 
12]. This will require communication and cooperation 
between investigators around the globe. Our section will 
provide such a forum for the exchange of ideas and unifi-
cation of procedures.
Conclusions
Clinical and Translational Medicine is launching a new 
section on stem cell therapies that will concentrate on 
experimental and clinical results for stem cell applica-
tions in regenerative medicine, stem cell isolation, and 
expansion, with a focus on stem cells isolated or derived 
from adult tissues, umbilical cord blood, umbilical cord, 
placenta, fat tissue, and myocardium. It will also deal with 
molecular mechanisms involved in stem cell pluripo-
tency, quiescence, proliferation, and differentiation and 
will cover mechanisms that regulate stem cell trafficking, 
including their mobilization into peripheral blood and 
homing to damaged tissues. Moreover, it will cover par-
acrine- and extracellular microvesicle-mediated effects 
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of stem cell therapies, clinical ethics, regulations, trials, 
protocols, and practices of stem cell therapies in regen-
erative medicine. We encourage investigators to submit 
their best work so that, if accepted, it will be immediately 
spread throughout the scientific community through the 
open access format of our journal. Our section will be 
wide open to new discoveries and challenging ideas and 
we would like to welcome and publish your best research.
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